NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
54,925,000
53,166,000
50,135,000
49,436,000
50,387,000
Cost of Revenue
18,368,000
18,407,000
17,175,000
17,520,000
17,404,000
Gross Profit
36,557,000
34,759,000
32,960,000
31,916,000
32,983,000
Operating Expenses
Research Development
9,368,000
9,074,000
8,972,000
9,039,000
8,935,000
Selling General and Administrative
16,895,000
16,471,000
14,997,000
14,192,000
14,247,000
Total Operating Expenses
28,166,000
26,590,000
24,331,000
23,648,000
24,006,000
Operating Income or Loss
8,391,000
8,169,000
8,629,000
8,268,000
8,977,000
Interest Expense
920,000
957,000
777,000
707,000
655,000
Total Other Income/Expenses Net
584,000
6,372,000
1,062,000
233,000
266,000
Income Before Tax
8,254,000
13,835,000
8,999,000
7,817,000
8,134,000
Income Tax Expense
1,202,000
1,221,000
1,296,000
1,119,000
1,106,000
Income from Continuing Operations
7,052,000
12,614,000
7,703,000
6,698,000
7,028,000
Net Income
11,802,000
12,611,000
7,703,000
6,712,000
17,783,000
Net Income available to common shareholders
11,802,000
12,611,000
7,703,000
6,712,000
17,783,000
Reported EPS
Basic
-
5.44
3.28
2.82
7.40
Diluted
-
5.38
3.25
2.80
7.29
Weighted average shares outstanding
Basic
-
2,319,000
2,346,000
2,378,000
2,403,000
Diluted
-
2,344,000
2,371,000
2,400,000
2,438,000
EBITDA
-
21,684,000
15,852,000
14,567,000
14,364,000